Total Voting Rights

Cambridge Cognition Holdings PLC
03 July 2023
 

3 July 2023

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Total Voting Rights

 

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, announces that pursuant to its block admission facility, details of which were announced on 21 March 2023, it has recently issued 37,444 new ordinary shares in the Company in satisfaction of the exercise of employee share options.  Accordingly, as at 30 June 2023 the Company has 34,852,833 ordinary shares in issue.

 

There are no shares held in treasury therefore the total number of voting rights in the Company is 34,852,833. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cambridge Cognition Holdings Plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

Tel: 020 3903 7715 

 

 

IFC Advisory Ltd (Financial PR and IR) 

Tim Metcalfe / Graham Herring / Zach Cohen 

 

Tel: 020 3934 6630 

 






 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
Investor Meets Company
UK 100